Saltar al contenido
Merck

AB7356

Anti-von Willebrand Factor Antibody

Chemicon®, from rabbit

Sinónimos:

Factor VIII Related Antigen

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño



About This Item

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702

Nombre del producto

Anti-von Willebrand Factor Antibody, Chemicon®, from rabbit

biological source

rabbit

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human, rat, mouse

packaging

antibody small pack of 25 μg

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunohistochemistry: suitable (paraffin)

NCBI accession no.

UniProt accession no.

shipped in

ambient

storage temp.

2-8°C

target post-translational modification

unmodified

Quality Level

Gene Information

human ... F8(302470), VWF(7450)
rat ... F8(302470)

Analysis Note

Immunohistochemistry(paraffin):
Representative images from a previous lot.
Rabbit anti-vWF (AB7356) staining of Human Cerebral Cortex. Tissue pretreated with Citrate Buffer, ph 6.0, anti-vWF at 20 μg/mL, IHC-Select Detection with HRP-DAB.

Application

Anti-von Willebrand Factor, Cat. No. AB7356, is a rabbit polyclonal antibody that detects von Willebrand Factor and has been tested for use in ELISA, Immunohistochemistry, and Western Blotting.
Immunohistochemistry Analysis: A representative lot detected von Willebrand Factor in Immunohistochemistry applications.

ELISA Analysis: A representative lot detected von Willebrand Factor in ELISA applications.

Immunohistochemistry Analysis: A 1:250-1,000 dilution from a representative lot detected von Willebrand Factor in human cerebral cortex, mouse hippocampus, rat cerebellum and human tonsil tissue sections.
Research Category
Cell Structure
Research Sub Category
ECM Proteins

Biochem/physiol Actions

AB7356 is specific for vWF by ELISA against the human protein and by immunohistochemistry. The antibody is reactive in paraffin embedded tissues on human, rat, and mouse. Other species not tested. Antibody has not been evaluated by western blot analysis for reactivity to vWF.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

250 kDa
This Anti-von Willebrand Factor Antibody is validated for use in ELISA, Immunohistochemistry (IHC) for the detection of von Willebrand Factor.
von Willebrand factor (UniProt: P04275; also known as vWF) is encoded by the VWF (also known as F8VWF) gene (Gene ID:7450) in human. vWF is a multimeric plasma glycoprotein that is synthesized by endothelial cells and plays an important in the maintenance of hemostasis. It is synthesized with a signal peptide (aa 1-22), which is subsequently cleaved off in the mature form. vWF is known to promote adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. vWF also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Mutations in VWF gene are linked to von Willebrand diseases 1-3 that are common hemorrhagic disorders caused by impaired platelet aggregation. Two isoforms of vWF have been described that are produced by alternative splicing.

Immunogen

Human von Willebrand Factor purified from plasma.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Format: Purified
Protein A purified
Purified rabbit immunoglobulin in buffer containing 0.02 M PBS pH 7.6, 0.25 M NaCl with 0.1% sodium azide.

Preparation Note

Stable for 1 year at 2-8ºC from date of receipt.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Clase de almacenamiento

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Antagonizing the ?v ?3 integrin inhibits angiogenesis and impairs woven but not lamellar bone formation induced by mechanical loading.
Tomlinson, RE; Schmieder, AH; Quirk, JD; Lanza, GM; Silva, MJ
Journal of Bone and Mineral Research null
Jason Baik et al.
PloS one, 7(10), e47494-e47494 (2012-10-17)
Clofazimine is a poorly-soluble but orally-bioavailable small molecule drug that massively accumulates in macrophages when administered over prolonged periods of time. To determine whether crystal-like drug inclusions (CLDIs) that form in subcellular spaces correspond to pure clofazimine crystals, macrophages of
Aleksander Skardal et al.
Stem cells translational medicine, 1(11), 792-802 (2012-12-01)
Stem cells obtained from amniotic fluid show high proliferative capacity in culture and multilineage differentiation potential. Because of the lack of significant immunogenicity and the ability of the amniotic fluid-derived stem (AFS) cells to modulate the inflammatory response, we investigated
Gage Brummer et al.
Molecular cancer research : MCR, 16(2), 296-308 (2017-11-15)
Ductal carcinoma in situ (DCIS) is the most common form of breast cancer, with 50,000 cases diagnosed every year in the United States. Overtreatment and undertreatment remain significant clinical challenges in patient care. Identifying key mechanisms associated with DCIS progression
John-Michael Arpino et al.
Circulation research, 120(9), 1453-1465 (2017-02-09)
Angiogenesis occurs after ischemic injury to skeletal muscle, and enhancing this response has been a therapeutic goal. However, to appropriately deliver oxygen, a precisely organized and exquisitely responsive microcirculation must form. Whether these network attributes exist in a regenerated microcirculation

Contenido relacionado

Immunoperoxidase Secondary Detection System

Número de artículo de comercio global

SKUGTIN
AB735604053252506710
AB7356-25UG04054839350313

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico